Company: CORT
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001628280-25-037005
Chunk: 244

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-07-31
Form: 10-Q
Item: Part II, Item 2
Chunk 244
---
 a net-share settlement of a cashless option exercise, of which 35,265 shares were surrendered to us. In June 2025, we issued 266,414 shares of common stock as part of a net-share settlement of a cashless option exercise, of which 129,315 shares were surrendered to us.

In April 2025, we issued 28,782 shares of common stock as part of restricted stock vesting, of which 10,681 shares were surrendered to us in satisfaction of related tax obligations. In May 2025, we issued 81,616 shares of common stock as part of restricted stock vesting, of which 29,906 shares were surrendered to us. In June 2025, we issued 68,245 shares of common stock as part of restricted stock vesting, of which 23,579 shares were surrendered to us.

(2) We paid $12.4 million to satisfy the tax withholding obligations associated with the net-share settlement of these cashless option exercises and vesting of restricted stock.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.  MINE SAFETY DISCLOSURES

Not applicable.

41

ITEM 5.  OTHER INFORMATION

Insider Trading Arrangements

During the three months ended June 30, 2025, no directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, terminated, or modified any contract, instruction or written plan for the purchase or sales of our securities intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.

42

ITEM 6.  EXHIBITSExhibitNumber Description of Document3.1 Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on May 24, 2023).3.2 Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on December 11, 2023).31.1 Rule 13a-14(a)/15d-14(a) Certifications of Joseph K. Belanoff, M.D., Chief Executive